Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Prospective Phase I/II, Single-Arm, Open-Label, Multicentre Study to Evaluate the Safety and Efficacy of Tafasitamab (MOR00208) in Pediatric Patients With Relapsed or Refractory Acute B Lineage Leukemia

NCT05366218 is registered in ClinicalTrials.gov with University Hospital Tuebingen as lead sponsor.

NCT NCT05366218
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05366218 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Prospective Phase I/II, Single-Arm, Open-Label, Multicentre Study to Evaluate the Safety and Efficacy of Tafasitamab (MOR00208) in Pediatric Patients With Relapsed or Refractory Acute B Lineage Leukemia
Lead sponsor
University Hospital Tuebingen
Phase
Phase 1/2
Overall status
Recruiting
Start date
March 8, 2023
Completion date
February 28, 2029
Enrollment
20 (estimated)
Sites
11

Conditions

As the registry lists them; a condition with its own page is linked.

acute lymphocytic leukemia refractory, acute lymphoid leukemia relapse, all, childhood b-cell